A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-Proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)

Trial Profile

A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-Proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Octreotide (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 09 Apr 2012 Status of extension trial (NCT00248131) is discontinued as reported by ClinicalTrials.gov
    • 09 Apr 2012 Status of extension trial (NCT00248131) is discontinued as reported by ClinicalTrials.gov
    • 09 Apr 2012 The actual end date for the extension trial (NCT00248131) is now July 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top